中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2013年
4期
33-36
,共4页
干扰素%核苷(酸)类似物%临床疗效
榦擾素%覈苷(痠)類似物%臨床療效
간우소%핵감(산)유사물%림상료효
Interferon%Nucleoside analogues%Clinical effect
目的：探讨HBsAg、HBeAg定量检测在CHB抗病毒治疗中的临床意义。方法选择本院门诊及住院CHB患者152例，应用干扰素、核苷（酸）类似物抗病毒治疗，在治疗前、12周、24周、52周定量检测HBsAg、HBeAg、HBV DNA定量，观察HBsAg、HBeAg与治疗疗效的相关性。结果干扰素治疗组12周HBeAg的变化及24周HBsAg变化与治疗远期效果有相关性，差异均有统计学意义（P均＜0.05）；核苷类似物治疗组HBsAg定量在治疗过程中变化不明显，12周、24周HBeAg变化与患者预后有关，差异均有统计学意义（P均＜0.05），HBeAg可做为预测耐药风险的参考指标。结论HBsAg、HBeAg是两个稳定、可靠的生物学标志，两者定量检测可以直观地分析患者病情变化，预测治疗应答情况，帮助制定个体化治疗方案。
目的：探討HBsAg、HBeAg定量檢測在CHB抗病毒治療中的臨床意義。方法選擇本院門診及住院CHB患者152例，應用榦擾素、覈苷（痠）類似物抗病毒治療，在治療前、12週、24週、52週定量檢測HBsAg、HBeAg、HBV DNA定量，觀察HBsAg、HBeAg與治療療效的相關性。結果榦擾素治療組12週HBeAg的變化及24週HBsAg變化與治療遠期效果有相關性，差異均有統計學意義（P均＜0.05）；覈苷類似物治療組HBsAg定量在治療過程中變化不明顯，12週、24週HBeAg變化與患者預後有關，差異均有統計學意義（P均＜0.05），HBeAg可做為預測耐藥風險的參攷指標。結論HBsAg、HBeAg是兩箇穩定、可靠的生物學標誌，兩者定量檢測可以直觀地分析患者病情變化，預測治療應答情況，幫助製定箇體化治療方案。
목적：탐토HBsAg、HBeAg정량검측재CHB항병독치료중적림상의의。방법선택본원문진급주원CHB환자152례，응용간우소、핵감（산）유사물항병독치료，재치료전、12주、24주、52주정량검측HBsAg、HBeAg、HBV DNA정량，관찰HBsAg、HBeAg여치료료효적상관성。결과간우소치료조12주HBeAg적변화급24주HBsAg변화여치료원기효과유상관성，차이균유통계학의의（P균＜0.05）；핵감유사물치료조HBsAg정량재치료과정중변화불명현，12주、24주HBeAg변화여환자예후유관，차이균유통계학의의（P균＜0.05），HBeAg가주위예측내약풍험적삼고지표。결론HBsAg、HBeAg시량개은정、가고적생물학표지，량자정량검측가이직관지분석환자병정변화，예측치료응답정황，방조제정개체화치료방안。
Objective To study the clinical significance of HBsAg and HBeAg quantitative detection in antiviral treatment. Methods Total of 152 patients with chronic hepatitis B selected from the author’s hospital received antiviral treatment with interferon and nucleoside analogues. After 12 weeks, 24 weeks and 52 weeks of treatment, quantitative detections of HBsAg, HBeAg and HBV DNA have been carried out so as to observe the correlation between the quantitative detection and the treatment effect. Results For the interferon treatment group:the changes of HBeAg after 12 weeks and HBeAg after 24 weeks have correlation with long-term outcome, which is of statistical signiifcance (both P<0.05);for the nucleoside analogues treatment group:HBsAg quantitative didn’t change signiifcantly in the course of treatment, and the changes of HBeAg after 12 weeks and 24 weeks have been found to be associated with the prognosis of the patients, which also has statistical signiifcance (both P<0.05);HBeAg can serve as a reference index for forecasting the risk of drug resistance. Conclusions HBsAg and HBeAg are two stable and reliable biological markers;the quantitative detection can visually analyze the patients’ conditional changes, predict therapeutic response and help formulate the individualized treatment plan.
